ETON Quote, Financials, Valuation and Earnings

Elutia has a net margin of 6.07% compared to Eton Pharmaceuticals's net margin of 21.72%. Eton Pharmaceuticals's return on equity of -35.45% beat Elutia's return on equity of --.

Eton Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 20%. On the other hand Elutia has an analysts' consensus of $10.00 which suggests that it could grow by 105.48%. Given that Elutia has higher upside potential than Eton Pharmaceuticals, analysts believe Elutia is more attractive than Eton Pharmaceuticals.

Eton Pharmaceuticals has a beta of 1.394, which suggesting that the stock is 39.406% more volatile than S&P 500. In comparison Elutia has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Eton Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elutia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals pays -- of its earnings as a dividend. Elutia pays out -- of its earnings as a dividend.

Eton Pharmaceuticals quarterly revenues are $10.3M, which are larger than Elutia quarterly revenues of $5.9M. Eton Pharmaceuticals's net income of $627K is lower than Elutia's net income of $1.3M. Notably, Eton Pharmaceuticals's price-to-earnings ratio is 79.75x while Elutia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals is 9.36x versus 4.75x for Elutia. Usually stocks with elevated PS ratios are considered overvalued.

iBio has a net margin of 6.07% compared to Eton Pharmaceuticals's net margin of -4444.57%. Eton Pharmaceuticals's return on equity of -35.45% beat iBio's return on equity of -148.3%.

Eton Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 20%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 52.54%. Given that iBio has higher upside potential than Eton Pharmaceuticals, analysts believe iBio is more attractive than Eton Pharmaceuticals.

Eton Pharmaceuticals has a beta of 1.394, which suggesting that the stock is 39.406% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Eton Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Eton Pharmaceuticals quarterly revenues are $10.3M, which are larger than iBio quarterly revenues of $175K. Eton Pharmaceuticals's net income of $627K is higher than iBio's net income of -$4M. Notably, Eton Pharmaceuticals's price-to-earnings ratio is 79.75x while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals is 9.36x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 6.07% compared to Eton Pharmaceuticals's net margin of -49.65%. Eton Pharmaceuticals's return on equity of -35.45% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Eton Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 20%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Eton Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Eton Pharmaceuticals.

Eton Pharmaceuticals has a beta of 1.394, which suggesting that the stock is 39.406% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Eton Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Eton Pharmaceuticals quarterly revenues are $10.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Eton Pharmaceuticals's net income of $627K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Eton Pharmaceuticals's price-to-earnings ratio is 79.75x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals is 9.36x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 6.07% compared to Eton Pharmaceuticals's net margin of -2357.27%. Eton Pharmaceuticals's return on equity of -35.45% beat Palatin Technologies's return on equity of --.

Eton Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 20%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Eton Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Eton Pharmaceuticals.

Eton Pharmaceuticals has a beta of 1.394, which suggesting that the stock is 39.406% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Eton Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eton Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Eton Pharmaceuticals quarterly revenues are $10.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Eton Pharmaceuticals's net income of $627K is higher than Palatin Technologies's net income of -$7.8M. Notably, Eton Pharmaceuticals's price-to-earnings ratio is 79.75x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eton Pharmaceuticals is 9.36x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.